During the past decade, RCC treatment has transitioned from a nonspecific immune approach to targeted therapy against vascular endothelial growth factor (VEGF) and now to novel immunotherapy agents (Siegel et al., 2016; Choueiri and Motzer, 2017). Here, VEGFA is linked to renal cell carcinoma.